Bicyclic PARP-1 Inhibitor Chemistry for Lower Off-Target Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PARP inhibitors exhibit non-selectivity, leading to adverse reactions such as intestinal toxicity and hematological toxicity, limiting their use in combination with chemotherapy drugs.
Innovation Solution
Development of a compound represented by formula (I), (III), (IV), or (V) that selectively inhibits PARP-1, with specific structural modifications to enhance selectivity, safety, and reduce side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-selective PARP inhibitors are used, then DNA repair inhibition is achieved, but intestinal toxicity and hematological toxicity occur
Solution Approach 1:
The patent applies local quality by designing a compound with specific structural features (bicyclic ring system with particular substituent patterns) that confer selective affinity for PARP-1 over other PARP family members. The molecular structure contains specific functional groups and spatial arrangements that target PARP-1's active site while avoiding off-target binding to PARP-2 and tankyrase, thereby achieving localized inhibition effect at the desired biological target.
Solution Approach 2:
The patent employs parameter changes by systematically modifying molecular parameters including substituent types, ring sizes, and stereochemical configurations to optimize selectivity. By varying these structural parameters, the compound achieves differential binding affinity where IC50 for PARP-1 is significantly lower than for PARP-2 and tankyrase, transforming the inhibition profile from non-selective to highly selective through controlled parameter adjustment.
2Adaptability or versatility
If non-selective PARP inhibitors are used, then broad PARP family inhibition is achieved, but selectivity against PARP-1 is lost
Solution Approach 1:
The compound exhibits local quality through its differentiated interaction with PARP-1 compared to other PARP family members. The bicyclic core structure with specific substituent patterns creates a binding interface that is optimally complementary to PARP-1's active site architecture, resulting in preferential binding and inhibition of PARP-1 while maintaining reduced affinity for PARP-2 and tankyrase.
Solution Approach 2:
The patent utilizes asymmetry in the molecular design where the compound possesses chiral centers and asymmetric substituent arrangements that create stereoselective binding. This asymmetric structure allows differential recognition by PARP-1 versus other PARP family members, achieving high enantioselectivity and target specificity through the spatial arrangement of functional groups that matches PARP-1's asymmetric binding pocket.
3Reliability
If current PARP inhibitors are used, then tumor cell killing effect is achieved, but adverse reactions limit combination with chemotherapy drugs
Solution Approach 1:
The patent converts the harmful non-selective inhibition into a beneficial selective inhibition by designing a compound that specifically targets PARP-1 while sparing PARP-2 and tankyrase. This selectivity transforms the previously harmful off-target effects into a therapeutic advantage, enabling safe combination with chemotherapy drugs by eliminating the toxicity mechanisms while preserving the synthetic lethal effect in HRD tumor cells.
Solution Approach 2:
The compound achieves improved therapeutic window through parameter changes in its molecular structure that optimize the ratio of target inhibition potency to off-target activity. By adjusting structural parameters to achieve nanomolar IC50 for PARP-1 with significantly higher selectivity margins, the compound enables combination therapy where the therapeutic benefit is enhanced while the adverse reaction profile is improved, allowing easier operational combination with chemotherapy regimens.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compound demonstrates good activity, low toxicity, high safety, strong selectivity, and good pharmacokinetics, providing a more effective treatment option for diseases related to PARP-1 inhibition.
Implementation Method 1
a small molecule compound having a PARP-1 inhibitory activity
Data Source
AI summary
Disclosed herein are a compound represented by formula (II) or a stereoisomer, a pharmaceutically acceptable salt, a solvate, a co-crystal or a deuterated form thereof, or a pharmaceutical composition comprising same, and use thereof as a PARP-1 inhibitor in preparing a medicament for treating a related disease. Groups in formula (II) are defined in the description.